Updated re­­sults of a Phase 1 trial testing bb2121 in re­lapsed mul­ti­ple myeloma patients were pre­sented last Friday at the American Society of Clinical Oncology (ASCO) annual meeting. bb2121 is a poten­tial new myeloma treat­ment in the chi­meric an­ti­gen re­cep­tor (CAR) T-cell class of ther­a­pies.

The re­­sults pre­sented at this year's ASCO meeting con­firm pre­vi­ous findings in­di­cating bb2121 has sub­stan­tial anti-myeloma ac­­tiv­ity.

At some of the higher doses of bb2121 tested during the trial, for example, nearly every patient treated with the drug responded to it; the over­all re­sponse rate was almost …

Die diesjährige Jahrestagung der American Society of Clinical Oncology (ASCO) begann am Freitag, den 1. Juni, und läuft bis zum Dienstag, den 5.Juni.

Jeden Tag gab es Vorträge über das multiple Myelom. Die Hauptveranstaltung mit Vorträgen über das Myelom fand jedoch am Freitag statt. Forschung, die in Vorträgen zusammengefasst wird, ist in der Regel besonders wichtig, entweder weil das Thema selbst wichtig ist oder weil die Ergebnisse auf umfangreichen Beweisen beruhen (z.B. einer umfangreichen klinischen Studie).

Angesichts der potenziellen Bedeutung der am vergangenen Freitag vorgestellten Forschungsergebnisse befragte Myeloma Beacon drei Myelomexperten zu …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began last Friday and will run through tomorrow.

Multiple myeloma-related pre­sen­ta­tions have been taking place every day of the meeting. The main myeloma-related oral pre­sen­ta­tion session of the meeting, how­ever, took place on Friday. Research summarized during oral pre­sen­ta­tion sessions usually is par­tic­u­larly im­por­tant, either because the subject itself is im­por­tant, or because the results are based on sub­stan­tial amounts of evi­dence (for example, a sizable clin­i­cal trial).

Given the poten­tial importance of the re­search results pre­sented last Friday, The Beacon asked …

• bluebird and Celgene will share 50% of U.S. costs and profits
• bluebird to re­ceive mile­stones and royalties on ex-U.S. sales

Cambridge, MA and Summit, NJ (Press Release) – bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corpo­ra­tion (Nasdaq: CELG) to­day an­nounced that the com­pa­nies have entered into an agree­ment to co-develop and co-promote bb2121, an inves­ti­ga­tional anti-B-cell maturation an­ti­gen (BCMA) chi­meric an­ti­gen re­cep­tor (CAR) T cell ther­apy for the poten­tial treat­ment of patients with re­lapsed/refractory mul­ti­ple myeloma in the United States.

“Entering into this co-development and co-promotion part­ner­ship with Celgene is a sig­nif­i­cant step for­ward in build­ing a fully integrated on­col­ogy fran­chise for bluebird and to­geth­er, …

Designations based on pre­lim­i­nary clin­i­cal data from on­go­ing phase I study of bb2121 in heavily pre-treated mul­ti­ple myeloma

Summit, NJ and Cambridge, MA (Press Release) – Celgene Corpo­ra­tion (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) to­day an­nounced that bb2121, a chi­meric an­ti­gen re­cep­tor T-cell (CAR-T) ther­apy targeting b-cell maturation an­ti­gen (BCMA) in pre­vi­ously treated patients with mul­ti­ple myeloma, has been granted Break­through Therapy Desig­na­tion (BTD) by the U.S. Food and Drug Admin­istra­tion (FDA) and PRIority MEdicines (PRIME) eligibility by the Euro­pean Medicines Agency (EMA).

BTD desig­na­tion and PRIME eligibility for bb2121 were based on pre­lim­i­nary clin­i­cal data from the on­go­ing phase 1 study CRB-401. Updated data from CRB-401 is scheduled to be …

• Celgene has agreed to exercise its op­tion to ex­clu­sively license bb2121 under global stra­te­gic col­lab­o­ration
• bluebird bio to re­ceive $10 million op­tion exercise pay­ment from Celgene

Cambridge, MA (Press Release) – bluebird bio, Inc. (Nasdaq:BLUE), a clin­i­cal-stage com­pany com­mit­ted to devel­op­ing poten­tially trans­for­ma­tive gene ther­a­pies for severe ge­netic dis­eases and T cell-based immuno­therapies for cancer, an­nounced treat­ment of the first patient in a Phase 1 study of its prod­uct can­di­date bb2121 in patients with re­lapsed / re­frac­tory mul­ti­ple myeloma. bb2121 is a chi­meric an­ti­gen re­cep­tor T cell (CAR T) ther­apy targeting B cell maturation an­ti­gen (BCMA), and bluebird bio is devel­op­ing bb2121 in col­lab­o­ration with Celgene Corpo­ra­tion. bluebird bio also …

Company to webcast in­­vestor event, Sunday, De­cem­ber 6 at 8:30 p.m. ET

Orlando, FL (Press Release) – bluebird bio, Inc. (NASDAQ:BLUE), a clin­i­cal-stage com­pany com­mit­ted to devel­op­ing poten­tially trans­for­ma­tive gene ther­a­pies for severe ge­netic dis­eases and T cell-based im­mun­o­therapies for cancer, an­nounced that pre-clinical data from its anti-BCMA on­col­ogy pro­gram were pre­sented by bluebird bio scientists at the 57th American Society of He­ma­tol­ogy Annual Meeting.

“We be­lieve the unique science and trans­la­tional gene ther­apy plat­forms we have built dif­fer­en­ti­ate bluebird bio in the on­col­ogy field and have the poten­tial to yield im­por­tant new ther­a­pies for patients living with can­cer. Our three on­col­ogy posters at …